Endo International PLC (NASDAQ:ENDP) had its target price lowered by equities researchers at Morgan Stanley from $12.00 to $8.00 in a report issued on Thursday. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 5.96% from the company’s current price.

Several other analysts have also commented on ENDP. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a research note on Tuesday. Cowen and Company reissued a “hold” rating and set a $16.00 target price on shares of Endo International PLC in a research note on Thursday. Royal Bank Of Canada set a $9.00 target price on shares of Endo International PLC and gave the company a “hold” rating in a research note on Thursday. Mizuho reissued a “buy” rating and set a $19.00 target price on shares of Endo International PLC in a research note on Thursday. Finally, Guggenheim began coverage on shares of Endo International PLC in a research note on Saturday, June 17th. They set a “hold” rating and a $12.00 target price for the company. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the company. Endo International PLC has a consensus rating of “Hold” and an average price target of $15.12.

Shares of Endo International PLC (NASDAQ:ENDP) traded down 4.91% on Thursday, hitting $7.55. 13,400,684 shares of the stock were exchanged. The firm’s 50-day moving average is $11.15 and its 200-day moving average is $11.62. The company’s market cap is $1.68 billion. Endo International PLC has a one year low of $7.52 and a one year high of $24.93.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. During the same period in the prior year, the business posted $0.86 EPS. The business’s revenue for the quarter was down 4.9% compared to the same quarter last year. On average, equities analysts forecast that Endo International PLC will post $3.52 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Cuts Endo International PLC (NASDAQ:ENDP) Price Target to $8.00” was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/10/morgan-stanley-cuts-endo-international-plc-nasdaqendp-price-target-to-8-00.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. raised its position in Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock valued at $107,000 after buying an additional 3,700 shares in the last quarter. James Investment Research Inc. bought a new position in Endo International PLC during the second quarter valued at $113,000. Blair William & Co. IL bought a new position in Endo International PLC during the second quarter valued at $126,000. Point View Wealth Management Inc. raised its position in Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares in the last quarter. Finally, Riverhead Capital Management LLC raised its position in Endo International PLC by 64.4% in the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares in the last quarter. Hedge funds and other institutional investors own 93.00% of the company’s stock.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.